AT-3 Xenograft Model Service for Breast Cancer

The AT-3 xenograft model is a sophisticated and highly aggressive syngeneic platform derived from the MTAG transgenic mouse, designed to closely mimic the progressive nature of human breast cancer. Alfa Cytology offers a specialized AT-3 xenograft model service, providing researchers with a clinically relevant in vivo tool to evaluate next-generation immunotherapies and targeted molecular treatments.

Overview of AT-3 Xenograft Model for Breast Cancer

The AT-3 model is a syngeneic mammary carcinoma model of particular importance due to its origin. It was isolated from an autochthonous mammary tumor in a transgenic MTAG mouse (on a C57BL/6 background). The MTAG model expresses the polyoma virus middle T antigen (PyMT) under the control of the MMTV-LTR promoter, a genetic configuration that leads to the development of mammary tumors that closely mirror the histological and molecular progression of human breast cancer.

Because AT-3 is derived from this specific transgenic lineage and transplanted into syngeneic C57BL/6 hosts, it provides an authentic in vivo environment with a fully functional immune system. This model is highly regarded for its aggressive growth and its ability to replicate the complex tumor-immune interactions found in human disease, making it a premier choice for testing checkpoint inhibitors and other immune-oncology interventions.

Fig 1. Absorbance values at 450 nm for anti-cTnI antibodies in non-tumor (control) and AT-3 tumor-bearing mice. (Xu S, et al., 2025)

Cell Line Information: AT-3

Our Services

Workflow of AT-3 Xenograft Model Construction

By choosing Alfa Cytology, you leverage our deep understanding of transgenic-derived syngeneic models. Our team ensures that the unique characteristics of the AT-3 line—such as its rapid proliferation and PyMT-driven signaling—are meticulously preserved throughout your in vivo studies, delivering high-impact data for your oncology pipeline.

• Cell Expansion: AT-3 cells are cultured in vitro in optimized media to maintain their aggressive tumorigenic phenotype.
• Host Selection: Syngeneic C57BL/6 female mice are selected to ensure a complete and compatible immune environment.
• Inoculation: Cells are precisely injected, typically into the mammary fat pad to simulate the orthotopic environment or subcutaneously for routine screening.
• Longitudinal Monitoring: We perform regular measurements of tumor volume and clinical observations to track disease progression.
• Endpoint Analysis: Comprehensive ex vivo analysis, including tumor-infiltrating lymphocyte (TIL) characterization and molecular signaling assays.

Fig 2. AT-3 Xenograft Model Construction Workflow

Case Study - AT-3 Xenograft Model Development

In a validation study conducted by Alfa Cytology, the AT-3 model demonstrated exceptional utility in studying the tumor microenvironment. Following orthotopic implantation, the tumors exhibited rapid growth and significant infiltration of myeloid-derived suppressor cells (MDSCs). Treatment with a combination of PyMT-targeted inhibitors and anti-PD-1 therapy resulted in measurable tumor regression, validating the model's sensitivity for complex therapeutic evaluations.

Why Choose Alfa Cytology?

• Scientific Precision: Expertise in PyMT-driven models and their clinical translatability.
• Immune Profiling: Advanced capabilities in analyzing the functional immune response within the AT-3 in vivo environment.
• Consistency: Rigorous cell line authentication and standardized inoculation protocols.
• Data-Driven Insights: We provide not just data, but expert interpretation to help move your project forward.

Contact Us

If you are looking to utilize a breast cancer model that truly reflects human disease progression, our AT-3 service is the ideal solution. Please reach out to us to consult with our lead scientists about your study design. Contact us today to see how Alfa Cytology can provide the high-quality in vivo evidence your research demands.

For research use only. Not intended for any clinical use.